文献速递前列腺癌

质谱成像用于前列腺癌诊断与特征分析

Prostate cancer diagnosis and characterization with mass spectrometry imaging.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-05

该综述检索2007年4月至2017年4月PubMed上关于质谱(MS)与质谱成像(MSI)在人前列腺癌中应用的全部文献,纳入报道前列腺癌特异性代谢物或可提示前列腺癌侵袭性代谢物的MSI研究。共识别出9项在完整人前列腺组织标本上开展的MSI关键研究,这些MSI检测的生物标志物在可靠识别前列腺癌和判断疾病侵袭性方面显示出前景。作者提出MSI可作为前列腺组织评估的辅助组织病理成像工具。

要点

  • MSI可检测区分良性前列腺组织与恶性前列腺组织的代谢物。
  • MSI检测的生物标志物在识别前列腺癌和判断疾病侵袭性方面显示出前景。
  • 作者提出MSI可作为前列腺组织评估的辅助组织病理成像工具。

核心结论

  • MSI是一种创新技术,能够结合组织病理学探查癌症生物标志物并研究肿瘤侵袭性。
  • 作者提出MSI作为前列腺组织评估的辅助组织病理成像工具,这一离体技术的临床转化可能使MSI用于前列腺癌诊断和预后的个体化医疗。

研究设计与样本

  • 综述:检索PubMed 2007年4月至2017年4月关于MS和MSI在人前列腺癌中应用的全部文献。
  • 纳入报道前列腺癌特异性代谢物或可提示前列腺癌侵袭性代谢物的MSI研究,以及涵盖MS和MSI原理、局限性和在前列腺癌中应用的文章。

主要发现

  • 识别出9项在完整人前列腺组织标本上开展的MSI关键研究,这些研究确定了可区分良性前列腺组织与恶性前列腺组织或提示前列腺癌侵袭性的代谢物。
  • 这些MSI检测的生物标志物在可靠识别前列腺癌和判断疾病侵袭性方面显示出前景。

临床怎么用

  • MSI可作为前列腺组织评估的辅助组织病理成像工具;该离体技术的临床转化可能使MSI用于前列腺癌诊断和预后的个体化医疗。
  • 该技术提供的知识可有助于理解前列腺癌和其他恶性疾病的分子发病机制。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa), the most common cancer and second leading cause of cancer death in American men, presents the clinical challenge of distinguishing between indolent and aggressive tumors for proper treatment. PCa presents significant alterations in metabolic pathways that can potentially be measured using techniques like mass spectrometry (MS) or MS imaging (MSI) and used to characterize PCa aggressiveness. MS quantifies metabolomic, proteomic, and lipidomic profiles of biological systems that can be further visualized for their spatial distributions through MSI. METHODS: PubMed was queried for all publications relating to MS and MSI in human PCa from April 2007 to April 2017. With the goal of reviewing the utility of MSI in diagnosis and prognostication of human PCa, MSI articles that reported investigations of PCa-specific metabolites or metabolites indicating PCa aggressiveness were selected for inclusion. Articles were included that covered MS and MSI principles, limitations, and applications in PCa. RESULTS: We identified nine key studies on MSI in intact human prostate tissue specimens that determined metabolites which could either differentiate between benign and malignant prostate tissue or indicate PCa aggressiveness. These MSI-detected biomarkers show promise in reliably identifying PCa and determining disease aggressiveness. CONCLUSIONS: MSI represents an innovative technique with the ability to interrogate cancer biomarkers in relation to tissue pathologies and investigate tumor aggressiveness. We propose MSI as a powerful adjuvant histopathology imaging tool for prostate tissue evaluations, where clinical translation of this ex vivo technique could make possible the use of MSI for personalized medicine in diagnosis and prognosis of PCa. Moreover, the knowledge provided from this technique can majorly contribute to the understanding of molecular pathogenesis of PCa and other malignant diseases.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Kurreck A, Vandergrift LA, Fuss TL, et al. Prostate cancer diagnosis and characterization with mass spectrometry imaging. Prostate Cancer Prostatic Dis. 2017. PMID: 29209003. doi:10.1038/s41391-017-0011-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。